Rhythm Pharmaceuticals (RYTM) Gross Margin (2021 - 2026)

Rhythm Pharmaceuticals (RYTM) has 6 years of Gross Margin data on file, last reported at 88.09% in Q1 2026.

• Gross Margin for Q1 2026 came in at 88.09%, down 75.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 89.41% (down 21.0% YoY), and the FY2025 annual result was 89.73%, changed 0.0% from the prior year.
• Gross Margin declined to 88.09% in Q1 2026 per RYTM's latest filing, from 91.61% in the prior quarter.
• Over five years, Gross Margin peaked at 112.77% in Q4 2022 and troughed at 84.65% in Q1 2022.
• A 5-year average of 90.5% and a median of 88.85% in 2025 frame the typical range for Gross Margin.
• The sharpest annual moves came in 2022 and 2023: Gross Margin surged 4583 bps in 2022, then slumped 2611 bps in 2023.
• A 5-year view of Gross Margin shows it stood at 112.77% in 2022, then retreated by 23 bps to 86.66% in 2023, then grew by 5 bps to 90.95% in 2024, then advanced by 1 bps to 91.61% in 2025, then dropped by 4 bps to 88.09% in 2026.
• Business Quant data shows RYTM's Gross Margin at 88.09% in Q1 2026, 91.61% in Q4 2025, and 89.28% in Q3 2025.